$ABCL
AbCellera Biologics Inc. Stock $abcl

$abcl Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000162828024045026 Filed on November 04, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$6.507M
YoY Change		-1.39%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$22.28M
YoY Change		24.92%
% of Gross Profit
Research & Development		$40.97M
YoY Change		8.05%
% of Gross Profit
Depreciation & Amortization		$3.800M
YoY Change		22.58%
% of Gross Profit
Operating Expenses		$100.2M
YoY Change		62.91%
Operating Profit		-$93.66M
YoY Change		70.64%
Interest Expense		$9.603M
YoY Change		-10.25%
% of Operating Profit
Other Income/Expense, Net		$31.03M
YoY Change		98.74%
Pretax Income		-$62.63M
YoY Change		59.47%
Income Tax		-$11.53M
% Of Pretax Income
Net Earnings		-$51.11M
YoY Change		78.63%
Net Earnings / Revenue		-785.42%
Basic Earnings Per Share		-$0.17
Diluted Earnings Per Share		-$0.17
COMMON SHARES
Basic Shares Outstanding	295.4M shares	294.7M shares
Diluted Shares Outstanding		294.9M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$643.1M
YoY Change		-18.15%
Cash & Equivalents		$126.6M
Short-Term Investments		$516.5M
Other Short-Term Assets		$43.37M
YoY Change		-39.11%
Inventory
Prepaid Expenses
Receivables		$31.37M
Other Receivables		$31.86M
Total Short-Term Assets		$742.9M
YoY Change		-19.21%
LONG-TERM ASSETS
Property, Plant & Equipment		$331.3M
YoY Change		19.5%
Goodwill		$47.81M
YoY Change		0.0%
Intangibles		$52.58M
YoY Change		-57.63%
Long-Term Investments		$84.08M
YoY Change		33.68%
Other Assets		$134.2M
YoY Change		66.33%
Total Long-Term Assets		$649.9M
YoY Change		9.66%
TOTAL ASSETS
Total Short-Term Assets		$742.9M
Total Long-Term Assets		$649.9M
Total Assets		$1.393B
YoY Change		-7.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$34.80M
YoY Change		99.97%
Accrued Expenses		$11.12M
YoY Change		-6.58%
Deferred Revenue		$5.578M
YoY Change		-68.14%
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$79.57M
YoY Change		-27.82%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$1.524M
YoY Change		-69.83%
Total Long-Term Liabilities		$235.2M
YoY Change		7.3%
TOTAL LIABILITIES
Total Short-Term Liabilities		$79.57M
Total Long-Term Liabilities		$235.2M
Total Liabilities		$314.7M
YoY Change		-4.46%
SHAREHOLDERS EQUITY
Retained Earnings		$151.1M
YoY Change		-53.77%
Common Stock		$928.2M
YoY Change		8.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$1.078B
YoY Change
Total Liabilities & Shareholders Equity		$1.393B
YoY Change		-7.89%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$51.11M
YoY Change		78.63%
Depreciation, Depletion And Amortization		$3.800M
YoY Change		22.58%
Cash From Operating Activities		-$28.88M
YoY Change		28782.0%
INVESTING ACTIVITIES
Capital Expenditures		$18.52M
YoY Change		-11.41%
Acquisitions
YoY Change
Other Investing Activities		$22.21M
YoY Change		174.25%
Cash From Investing Activities		$3.698M
YoY Change		-128.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		3.145M
YoY Change		-52.35%
NET CHANGE
Cash From Operating Activities		-28.88M
Cash From Investing Activities		3.698M
Cash From Financing Activities		3.145M
Net Change In Cash		-22.04M
YoY Change		249.83%
FREE CASH FLOW
Cash From Operating Activities		-$28.88M
Capital Expenditures		$18.52M
Free Cash Flow		-$47.40M
YoY Change		125.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Registrant Name EntityRegistrantName	AbCellera Biologics Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2215 Yukon Street
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	295366280	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133320000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126640000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	627265000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	516499000	usd
CY2023Q4	abcl	Accounts And Accrued Receivable Current AccountsAndAccruedReceivableCurrent	30590000	usd
CY2024Q3	abcl	Accounts And Accrued Receivable Current AccountsAndAccruedReceivableCurrent	31373000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	55810000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	43371000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	871985000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	742883000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120425000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	52577000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	47806000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	47806000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	65938000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1078094000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	293930702	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	43371000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	28603000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	34795000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	41128000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	33890000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4100000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	11000000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-69000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	488000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50266000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-99317000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-128159000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	dei	Entity Central Index Key EntityCentralIndexKey	0001703057
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	760585000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	643139000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	25000000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	25000000	usd
CY2023Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization	287696000	usd
CY2024Q3	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization	331263000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	49580000	usd
CY2024Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	53773000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	18958000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5578000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	8195000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4441000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6599000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6507000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28846000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23783000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37917000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40969000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	127036000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	121183000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3468000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3135000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11080000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9635000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14369000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19147000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45025000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	56691000	usd
CY2023Q3	abcl	Depreciation Amortization And Impairment DepreciationAmortizationAndImpairment	5735000	usd
CY2024Q3	abcl	Depreciation Amortization And Impairment DepreciationAmortizationAndImpairment	36919000	usd
	abcl	Depreciation Amortization And Impairment DepreciationAmortizationAndImpairment	16859000	usd
	abcl	Depreciation Amortization And Impairment DepreciationAmortizationAndImpairment	78285000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	61489000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	100170000	usd
	us-gaap	Operating Expenses OperatingExpenses	200000000	usd
CY2024Q3	abcl	Grants And Incentives GrantsAndIncentives	3491000	usd
	abcl	Grants And Incentives GrantsAndIncentives	10779000	usd
	abcl	Grants And Incentives GrantsAndIncentives	10076000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2046000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17937000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3670000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	48564000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15614000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	88445000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39276000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-62632000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-153566000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10666000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-11525000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-26179000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24919000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-28610000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-51107000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-99248000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-128647000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	439000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	841000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28171000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	289496841	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	294851945	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	288750387	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	293930702	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	289496841	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	294851945	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	288750387	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	293930702	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1152318000	usd
CY2024Q1	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	892000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17409000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-96000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-40610000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	1129913000	usd
CY2024Q2	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	460000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17782000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-257000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-36930000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	1110968000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-630000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40110000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1208500000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.abcellera.com/20240930#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.abcellera.com/20240930#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2024Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccountsPayableAndOtherAccruedLiabilitiesCurrent
	dei	Document Type DocumentType	10-Q
	dei	Entity File Number EntityFileNumber	001-39781
	dei	Entity Address City Or Town EntityAddressCityOrTown	Vancouver
	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V5Y 0A1
	dei	City Area Code CityAreaCode	604
	dei	Local Phone Number LocalPhoneNumber	559-9005
	dei	Security12b Title Security12bTitle	Common shares, no par value per share
	dei	Trading Symbol TradingSymbol	ABCL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	84084000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	94244000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	134215000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	616109000	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	649945000	usd
CY2023Q4	us-gaap	Assets Assets	1488094000	usd
CY2024Q3	us-gaap	Assets Assets	1392828000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	50475000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	20217000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	119013000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	79568000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	71222000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	66274000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	8100000	usd
CY2023Q4	us-gaap	Government Assistance Liability Noncurrent GovernmentAssistanceLiabilityNoncurrent	95915000	usd
CY2024Q3	us-gaap	Government Assistance Liability Noncurrent GovernmentAssistanceLiabilityNoncurrent	142046000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4913000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	30612000	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12781000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5906000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1524000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	216763000	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	235166000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	335776000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	314734000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2024Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	290824970	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	290824970	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	295157474	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	295157474	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	753199000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	772832000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	121052000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	155354000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1720000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1232000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	279787000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	151140000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1152318000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1078094000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1488094000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1392828000	usd
	us-gaap	Operating Expenses OperatingExpenses	265794000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-54890000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-93663000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-171154000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-242011000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	10740000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	9603000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	31278000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	29805000	usd
CY2023Q3	abcl	Grants And Incentives GrantsAndIncentives	2828000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	31031000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	45727000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-125427000	usd
CY2024Q3	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	228000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17164000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	841000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-51107000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1233277000	usd
CY2023Q1	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	489000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15474000	usd
CY2023Q2	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	334000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16399000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	122000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-30528000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1194827000	usd
CY2023Q3	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	257000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15862000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	439000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-28610000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1182775000	usd
	us-gaap	Profit Loss ProfitLoss	-99248000	usd
	us-gaap	Profit Loss ProfitLoss	-128647000	usd
	us-gaap	Depreciation Depreciation	8874000	usd
	us-gaap	Depreciation Depreciation	10437000	usd
	abcl	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	7985000	usd
	abcl	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	67848000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4926000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4813000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	47735000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	52355000	usd
	abcl	Gain On Contingent Consideration GainOnContingentConsideration	0	usd
	abcl	Gain On Contingent Consideration GainOnContingentConsideration	48727000	usd
	abcl	Deferred Income Tax And Other DeferredIncomeTaxAndOther	-6354000	usd
	abcl	Deferred Income Tax And Other DeferredIncomeTaxAndOther	-17891000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	35495000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	54258000	usd
	abcl	Increase Decrease In Accrued Royalties Receivable IncreaseDecreaseInAccruedRoyaltiesReceivable	-9273000	usd
	abcl	Increase Decrease In Accrued Royalties Receivable IncreaseDecreaseInAccruedRoyaltiesReceivable	0	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	28685000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-8709000	usd
	abcl	Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable	-1852000	usd
	abcl	Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable	4018000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-7238000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-13474000	usd
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-16253000	usd
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	0	usd
	abcl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-30377000	usd
	abcl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-30671000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4319000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1008000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24266000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-100556000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	62516000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	62766000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	744674000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	612249000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	642913000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	735989000	usd
	abcl	Proceeds From Receipt Of Grant Funding ProceedsFromReceiptOfGrantFunding	15023000	usd
	abcl	Proceeds From Receipt Of Grant Funding ProceedsFromReceiptOfGrantFunding	29150000	usd
	abcl	Payments To Acquire Long Term Investments And Other Assets PaymentsToAcquireLongTermInvestmentsAndOtherAssets	37317000	usd
	abcl	Payments To Acquire Long Term Investments And Other Assets PaymentsToAcquireLongTermInvestmentsAndOtherAssets	-13538000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	10214000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	17956000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-196785000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	85706000	usd
	abcl	Payments Of Liability For In Licensing Agreement And Other PaymentsOfLiabilityForInLicensingAgreementAndOther	1049000	usd
	abcl	Payments Of Liability For In Licensing Agreement And Other PaymentsOfLiabilityForInLicensingAgreementAndOther	552000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	6560000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	7599000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1080000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1580000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6591000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8627000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-479000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-457000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-214939000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6680000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	414651000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	160610000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	199712000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153930000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2290000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2290000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197422000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151640000	usd
	abcl	Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable	12948000	usd
	abcl	Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable	15989000	usd
	abcl	Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation	3586000	usd
	abcl	Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation	2232000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of operations<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbCellera Biologics Inc.’s (the “Company”) mission is to bring better antibody drugs to patients faster, solve long-standing problems, and transform how antibody drugs are discovered. The Company aims to bring antibody therapeutics from target to clinic by combining expertise, technologies, and infrastructure to build an engine for antibody drug discovery and development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty (and equivalent) stakes in future antibody drugs and to develop its own pipeline of future antibody drugs. The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling programs to the clinic, together</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div>The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, the impairment assessment of intangible assets and goodwill, and contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28610000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-28610000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-51107000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-51107000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-99248000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-99248000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-128647000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-128647000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	289496841	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	289496841	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	294851945	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	294851945	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	288750387	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	288750387	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	293930702	shares
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50081069	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50544294	shares
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	58027706	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	58543314	shares
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	73141000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	68319000	usd
CY2023Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsBeforeAccumulatedDepreciationAndAmortization	318304000	usd
CY2024Q3	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsBeforeAccumulatedDepreciationAndAmortization	369981000	usd
CY2023Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAccumulatedDepreciationAndAmortization	30608000	usd
CY2024Q3	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAccumulatedDepreciationAndAmortization	38718000	usd
CY2023Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization	287696000	usd
CY2024Q3	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization	331263000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	3100000	usd
	us-gaap	Depreciation Depreciation	8900000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	3800000	usd
	us-gaap	Depreciation Depreciation	10400000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	155143000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	34718000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120425000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	91133000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	38556000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	52577000	usd
CY2024Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	32000000	usd
CY2024Q3	abcl	Impairment Of Intangible Assets Finite Lived Net Of Deferred Income Tax ImpairmentOfIntangibleAssetsFiniteLivedNetOfDeferredIncomeTax	23300000	usd
CY2024Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	32000000	usd
CY2024Q2	abcl	Impairment Of Intangible Assets Finite Lived Net Of Deferred Income Tax ImpairmentOfIntangibleAssetsFiniteLivedNetOfDeferredIncomeTax	23700000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	4297000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	4297000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	4297000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	4297000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	4297000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21485000	usd
	abcl	Number Of Joint Ventures NumberOfJointVentures	2	jointventure
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	33792000	usd
CY2024Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	31863000	usd
CY2023Q4	abcl	Prepaid Expense And Other Current PrepaidExpenseAndOtherCurrent	22018000	usd
CY2024Q3	abcl	Prepaid Expense And Other Current PrepaidExpenseAndOtherCurrent	11508000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	55810000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6158000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5125000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7707000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5992000	usd
CY2023Q4	abcl	Deferred Grant Funding Current DeferredGrantFundingCurrent	7112000	usd
CY2024Q3	abcl	Deferred Grant Funding Current DeferredGrantFundingCurrent	7861000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	49580000	usd
CY2024Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	53773000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15862000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17164000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	47735000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52355000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	27153000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	13678000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5900000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	18900000	usd
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	32300000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	32300000	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	16500000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P0Y6M
	us-gaap	Royalty Expense RoyaltyExpense	0	usd
	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2024Q3	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2023Q3	us-gaap	Royalty Expense RoyaltyExpense	0	usd
	abcl	Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag	Government Contribution 1 (Canada)
CY2024Q3	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	52129000	usd
CY2024Q3	us-gaap	Government Assistance Liability GovernmentAssistanceLiability	149907000	usd
CY2023Q4	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	36051000	usd
CY2023Q4	us-gaap	Government Assistance Liability GovernmentAssistanceLiability	103027000	usd
CY2024Q3	us-gaap	Government Assistance Amount Cumulative Current GovernmentAssistanceAmountCumulativeCurrent	27053000	usd
CY2024Q3	us-gaap	Government Assistance Liability Current GovernmentAssistanceLiabilityCurrent	7861000	usd
CY2024Q3	us-gaap	Government Assistance Amount Cumulative Noncurrent GovernmentAssistanceAmountCumulativeNoncurrent	25076000	usd
CY2024Q3	us-gaap	Government Assistance Liability Noncurrent GovernmentAssistanceLiabilityNoncurrent	142046000	usd
	us-gaap	Government Assistance Transaction Duration GovernmentAssistanceTransactionDuration	P8Y
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-045026-index-headers.html	Edgar Link	pending
0001628280-24-045026-index.html	Edgar Link	pending
0001628280-24-045026.txt	Edgar Link	pending
0001628280-24-045026-xbrl.zip	Edgar Link	pending
abcl-20240930.htm	Edgar Link	pending
abcl-20240930.xsd	Edgar Link	pending
abcl-20240930xexx311.htm	Edgar Link	pending
abcl-20240930xexx312.htm	Edgar Link	pending
abcl-20240930xexx321.htm	Edgar Link	pending
abcl-20240930xexx322.htm	Edgar Link	pending
abcl-20240930_cal.xml	Edgar Link	unprocessable
abcl-20240930_g1.jpg	Edgar Link	pending
abcl-20240930_def.xml	Edgar Link	unprocessable
abcl-20240930_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
abcl-20240930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
abcl-20240930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABCL
AbCellera Biologics Inc. Stock $abcl

2024 Q4 Form 10-Q Financial Statement

#000162828024045026 Filed on November 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABCL AbCellera Biologics Inc. Stock $abcl

2024 Q4 Form 10-Q Financial Statement

#000162828024045026 Filed on November 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABCL
AbCellera Biologics Inc. Stock $abcl